GoodRx Holdings, Inc. (NASDAQ:GDRX) Given Average Rating of “Hold” by Brokerages

GoodRx Holdings, Inc. (NASDAQ:GDRXGet Rating) has been assigned a consensus recommendation of “Hold” from the nineteen ratings firms that are covering the firm, MarketBeat.com reports. Two investment analysts have rated the stock with a sell rating, six have issued a hold rating and ten have given a buy rating to the company. The average 12 month price target among brokers that have updated their coverage on the stock in the last year is $30.22.

A number of research firms have weighed in on GDRX. Royal Bank of Canada lowered their price objective on GoodRx from $50.00 to $35.00 and set an “outperform” rating on the stock in a research note on Tuesday, March 1st. Deutsche Bank Aktiengesellschaft cut their price target on shares of GoodRx from $25.00 to $20.00 and set a “hold” rating for the company in a report on Wednesday, March 2nd. Zacks Investment Research cut GoodRx from a “hold” rating to a “strong sell” rating in a report on Monday, March 7th. Cowen cut GoodRx from an “outperform” rating to a “market perform” rating and cut their target price for the stock from $49.00 to $22.00 in a research note on Tuesday, March 1st. Finally, Guggenheim assumed coverage on GoodRx in a research report on Wednesday, April 6th. They set a “buy” rating and a $24.00 price objective for the company.

NASDAQ:GDRX opened at $16.65 on Friday. The company has a debt-to-equity ratio of 0.79, a quick ratio of 13.42 and a current ratio of 13.42. The stock has a market capitalization of $6.67 billion, a PE ratio of -237.82, a P/E/G ratio of 6.45 and a beta of -0.47. GoodRx has a fifty-two week low of $13.44 and a fifty-two week high of $48.05. The company has a fifty day moving average of $19.37 and a two-hundred day moving average of $30.07.

GoodRx (NASDAQ:GDRXGet Rating) last released its earnings results on Monday, February 28th. The company reported $0.01 EPS for the quarter, missing analysts’ consensus estimates of $0.03 by ($0.02). The company had revenue of $213.30 million for the quarter, compared to analysts’ expectations of $217.51 million. GoodRx had a positive return on equity of 0.06% and a negative net margin of 3.39%. The firm’s revenue for the quarter was up 39.0% on a year-over-year basis. During the same period in the prior year, the firm earned ($0.60) EPS. Research analysts forecast that GoodRx will post 0.17 earnings per share for the current year.

A number of hedge funds have recently bought and sold shares of the stock. Morgan Stanley lifted its stake in GoodRx by 15.7% during the third quarter. Morgan Stanley now owns 4,705,001 shares of the company’s stock worth $192,999,000 after purchasing an additional 639,551 shares during the last quarter. Goldman Sachs Group Inc. lifted its stake in GoodRx by 62.1% during the fourth quarter. Goldman Sachs Group Inc. now owns 1,939,071 shares of the company’s stock worth $63,369,000 after purchasing an additional 742,906 shares during the last quarter. Darlington Partners Capital Management LP purchased a new stake in GoodRx during the fourth quarter worth approximately $52,276,000. Marshall Wace LLP lifted its stake in GoodRx by 10.4% during the fourth quarter. Marshall Wace LLP now owns 1,088,498 shares of the company’s stock worth $35,569,000 after purchasing an additional 102,426 shares during the last quarter. Finally, Petrus Trust Company LTA purchased a new stake in GoodRx during the third quarter worth approximately $32,047,000. Hedge funds and other institutional investors own 54.43% of the company’s stock.

About GoodRx (Get Rating)

GoodRx Holdings, Inc, through its subsidiaries, offers information and tools that enable consumers to compare prices and save on their prescription drug purchases in the United States. The company operates a price comparison platform that provides consumers with curated, geographically relevant prescription pricing, and access to negotiated prices through GoodRx codes that are used to save money on prescriptions across the United States.

Featured Stories

Analyst Recommendations for GoodRx (NASDAQ:GDRX)

Receive News & Ratings for GoodRx Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GoodRx and related companies with MarketBeat.com's FREE daily email newsletter.